NASDAQ · Medical - Devices

NSPR (NSPR) Stock

$0.69 +0.87% NASDAQ: NSPR Healthcare

Valuation

MetricValue
Price$0.69
Market Cap$32.30M
P/E Ratio-1.21
P/B Ratio0.79
P/S Ratio3.28
EPS (TTM)$-0.61
52-Week High$2.93
52-Week Low$0.64
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-142.60%
ROA-68.49%
ROCE-89.09%
Gross Margin28.06%
Operating Margin-4.81%
Net Margin-3.44%
Debt/Equity0.07
Current Ratio5.55

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.0M$5.0M$6.0M$7.0M$9.0M
Operating Profit$-15.0M$-19.0M$-21.0M$-34.0M$-49.0M
Net Profit$-15.0M$-18.0M$-20.0M$-32.0M$-49.0M
EPS$-2.03$-2.35$-0.82$-0.76$-0.76
Op Margin-327.4%-361.9%-340.7%-478.0%-547.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$40.0M$25.0M$48.0M$47.0M$69.0M
Total Liabilities$6.0M$7.0M$8.0M$11.0M$14.0M
Cash$12.0M$5.0M$10.0M$19.0M$9.0M
Borrowings$1.0M$2.0M$2.0M$2.0M$3.0M

Latest News

InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR Zacks · Jun 16, 2026 InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jun 12, 2026 InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures GlobeNewswire · Jun 11, 2026 InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures GlobeNewswire · Jun 8, 2026 InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference GlobeNewswire · May 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-13.0M$-16.0M$-16.0M$-22.0M$-35.0M
Investing Cash Flow$-23.0M$8.0M$-16.0M$11.0M$-32.0M
Financing Cash Flow$0$0$0$17.0M$0
Net Cash Flow$-1.0M$-7.0M$5.0M$9.0M$-10.0M
Free Cash Flow$-14.0M$-16.0M$-17.0M$-23.0M$-37.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA0.06
FCF Yield-112.92%
Quick Ratio4.82
Interest Coverage—
Return 1Y-68.70%
Return 3Y-77.14%
Return 5Y-83.33%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CNTX $0.62 +4.47% -6.84 $56.69M 0.00%
EDAPEdap Tms S.a. $4.76 -0.52% -6.63 $178.23M 0.00%
FONR $19.09 +0.00% 15.33 $117.76M 0.00%
HYPR $0.94 +0.99% -3.44 $78.94M 0.00%
IMA $5.69 +1.07% -1.49 $64.18M 0.00%

About NSPR

NSPR is led by CEO Marvin L. Slosman, employs 85 people, headquartered in IL, publicly traded since 2011.

NSPR stock trades at $0.69 with a market capitalization of $32.30M. The stock is valued at a price-to-earnings (P/E) ratio of -1.21, price-to-book of 0.79, price-to-sales of 3.28. Over the past 52 weeks the stock has ranged between $0.64 and $2.93, and currently trades 76.5% below its 52-week high.

On profitability, NSPR generates a return on equity (ROE) of -142.60%, return on capital employed of -89.09%, an operating margin of -4.81%, a net profit margin of -3.44%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides